✉ Email this page to a colleague
« Back to Dashboard
Avigan is an investigational drug.
There have been 17 clinical trials for Avigan. The most recent clinical trial was a Phase 2 trial, which was initiated on August 20th 2020.
The most common disease conditions in clinical trials are COVID-19, Hemorrhagic Fever, Ebola, and Lassa Fever. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti, and Institut National de la Santé Et de la Recherche Médicale, France.
There are one hundred and thirty-two US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Avigan
|Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever||Alliance for International Medical Action||Phase 2|
|Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever||Federal Medical Centre, Owo||Phase 2|
|Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever||Institut National de la Santé Et de la Recherche Médicale, France||Phase 2|
Top disease conditions for Avigan
Top clinical trial sponsors for Avigan
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Avigan||See Plans and Pricing||Methods and compositions for inhibition of polymerase||BioCryst Pharmaceuticals, Inc. (Durham, NC)||See Plans and Pricing|
|Avigan||See Plans and Pricing||Methods of preparing inhibitors of influenza viruses replication||Vertex Pharmaceuticals Incorporated (Boston, MA)||See Plans and Pricing|
|Avigan||See Plans and Pricing||Viral prophylaxis treatment methods and pre-exposure prophylaxis kits||ELIAN LLC (Monrovia, CA)||See Plans and Pricing|
|Avigan||See Plans and Pricing||Substituted nucleosides, nucleotides and analogs thereof||Alios BioPharma, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Avigan||Australia||AU2011315902||2030-10-15||See Plans and Pricing|
|Avigan||Australia||AU2017200471||2030-10-15||See Plans and Pricing|
|Avigan||Brazil||BR112013009029||2030-10-15||See Plans and Pricing|
|Avigan||Canada||CA2813783||2030-10-15||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|